Our approach to medicine is constantly evolving. For decades, cancer screening has focused on one part of the body at a time, based on specific risks and ages. This was the best method we had, but it left major gaps, unable to screen for many deadly cancers. It simply wasn’t designed to look everywhere. Now, science offers a new way forward. A modern cancer screening test can detect signals from dozens of cancer types with a single blood draw, giving us a more complete picture of our health.
That model has saved lives. But it also means most screening is still gated by age or risk factors: You turn 55. You smoke. You have a family history of breast cancer.
With this approach, many cancers are only discovered after symptoms appear, and patients are left playing catch-up, resorting to scorched-earth treatments like chemotherapy and radiation.
When cancer is identified early - before it spreads - treatment options expand and five-year survival rates can be up to four times higher than when diagnosed at later stages.¹
Still, our system still depends on waiting for the right trigger to begin testing. With nearly one in two Americans expected to face cancer in their lifetime, this is an ineffective way to manage a disease.
Is Your Current Cancer Screening Enough?
Here’s the gap: Even though 40% of people develop cancer in their lifetimeonly ~14% of cancers in the U.S. are detected through recommended screening.2,3
Most are still found only after symptoms emerge, when disease is often more advanced and harder to treat.
At the same time, cancer incidence in younger adults continues to rise, but screening hasn’t kept pace. It was designed for a world where cancer was rare in younger people and slow to emerge. That is no longer the world we live in.
This is where new technology begins to matter.
Understanding the Fundamentals of Cancer Screening
Before we can talk about the future of cancer detection, it’s important to understand the tools we have today. Traditional cancer screening is built on a simple, powerful idea: finding cancer before it causes symptoms. When a disease is caught in its earliest stages, treatment is often more effective and less invasive, which can dramatically improve outcomes. Think of it as the difference between finding a small, contained fire versus a house that’s already engulfed in flames. The goal of screening is to spot the smoke before you ever see the fire.
This proactive approach is the foundation of preventive health. It’s about shifting from a reactive model of treating sickness to a forward-thinking one that maintains wellness. The best-case scenario in screening isn’t just finding cancer early, it’s stopping it from ever forming in the first place. Many screening tests are designed to do just that by identifying pre-cancerous changes, which are abnormal cells that could one day become malignant. Finding and removing these cells is one of the most effective preventive measures in modern medicine.
The Purpose of Screening: Finding Cancer Early
The core purpose of any cancer screening test is to detect disease in people who have no symptoms. According to the Centers for Disease Control and Prevention (CDC)finding cancer early means treatment is more likely to work well. This early detection can be the key to turning a potentially devastating diagnosis into a manageable health condition. It gives you and your doctors more options and more time to act, which is a significant advantage in any health challenge. It’s about taking control by looking for potential issues on your own terms, not waiting for them to announce themselves.
Finding Pre-Cancerous Changes
Beyond just early detection, some of the most effective screening methods can identify "pre-cancers." The American Cancer Society describes these as abnormal cells that have the potential to turn into cancer. A perfect example is the removal of polyps during a colonoscopy. By removing these growths before they have a chance to become malignant, the screening procedure itself becomes a preventive treatment. This is the ultimate goal of proactive health: to intervene so early that the disease never even gets a chance to develop, preserving your long-term health and performance.
Types of Screening Methods
When your doctor recommends a cancer screening, it will typically fall into one of three main categories. Each method offers a different way of looking for signs of disease, from creating detailed pictures of your internal organs to analyzing your blood for specific biological clues. Understanding these different approaches can help you feel more prepared and informed about your own health plan. The type of test used often depends on the specific cancer being screened for, as well as your individual risk factors and medical history.
Imaging Tests
Imaging tests are essentially ways of taking pictures inside your body to look for abnormalities without making a single incision. You’re likely familiar with some of them already. A mammogram uses low-dose X-rays to examine breast tissue, while a low-dose computed tomography (LDCT) scan creates detailed cross-sectional images of the lungs. These tests are invaluable for spotting tumors or other suspicious changes that can't be seen or felt from the outside, giving doctors a non-invasive window into your body’s inner workings.
Medical Procedures
Some screening methods are more hands-on. These are medical procedures where a doctor uses specialized tools to look directly inside certain parts of the body. The most common example is a colonoscopy, where a thin, flexible tube is used to examine the entire colon and rectum. As the CDC explainsthis test is unique because it allows a doctor to both find and remove most pre-cancerous polyps during the same procedure. While more invasive than an imaging test, this dual diagnostic and therapeutic capability makes it incredibly effective.
Lab and At-Home Tests
This category includes tests that analyze samples like blood, urine, or stool for signs of disease. For instance, at-home stool tests can check for hidden blood or altered DNA that might indicate colorectal cancer. Blood tests are also common, such as the PSA test for prostate cancer. These tests look for specific biomarkers, measurable substances that can indicate a particular biological state. While a single test like the PSA looks for one specific marker, more advanced health assessments rely on comprehensive biomarker analysis to build a much broader and more detailed picture of your overall health.
Potential Risks and Limitations of Any Screening Test
While screening can be a life-saving tool, it’s important to have a clear-eyed view of its limitations. No test is perfect, and the process isn't entirely without risk. Being aware of the potential downsides isn't meant to discourage you from getting screened, but to ensure you can have a more informed conversation with your doctor about what’s right for you. The main challenges with any screening test are the possibilities of incorrect results and the complex issue of overdiagnosis, both of which can lead to unnecessary stress and medical procedures.
False Positives and Unnecessary Stress
One of the most significant downsides of screening is the risk of a false positive. This is when a test result suggests that you have cancer when you actually don’t. A false positive can trigger a cascade of anxiety, follow-up appointments, and sometimes invasive procedures like biopsies, all to confirm that there was no cancer to begin with. As the Cleveland Clinic notes, these incorrect results can delay necessary care for other issues or cause significant emotional distress, which is a real consideration in the screening process.
Overdiagnosis and Overtreatment
A more complex issue is overdiagnosis. This happens when a screening test finds a cancer that is so slow-growing it would never have caused any symptoms or problems during a person's lifetime. However, once it's found, it's nearly impossible to distinguish from a more aggressive cancer, leading to treatments like surgery, radiation, or chemotherapy that may not have been necessary. This "overtreatment" exposes a person to the potential side effects of treatment without providing any real health benefit, highlighting the delicate balance doctors must strike when recommending screening.
A Look at Standard Cancer Screening Guidelines
So, how do doctors decide who should be screened, for what, and when? These decisions aren't made on a whim. They are based on extensive research and recommendations from expert panels that weigh the potential benefits of a screening test against its potential harms. These guidelines are designed for people with an "average risk" of cancer, meaning they don't have a strong family history, a known genetic mutation, or other specific factors that would put them in a high-risk category. They serve as a baseline for the general population, providing a structured framework for preventive care.
These standard guidelines are why your doctor might start recommending mammograms when you turn 40 or colonoscopies when you turn 45. The recommendations are tied to age because the risk for most cancers increases as we get older. The goal is to apply these life-saving tests to the populations who are most likely to benefit from them, while minimizing the risks of overdiagnosis and false positives for those at lower risk. It’s a population-level strategy, but it’s the starting point for most personal screening conversations.
Specific Guidelines for Average-Risk Adults
For adults who are considered to be at average risk, screening guidelines generally focus on a handful of common cancers where early detection has been proven to save lives. These recommendations are the bedrock of our current preventive health system. They are typically issued by organizations like the U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society. While the exact age and frequency can vary slightly between organizations, the general consensus covers five main types of cancer, each with its own specific screening protocol designed for maximum benefit and minimum harm.
Breast Cancer
For women, mammograms are the most effective tool for finding breast cancer early. These specialized X-rays of the breast can detect tumors long before they are large enough to be felt. Guidelines generally recommend that women begin regular mammograms in their 40s, though the exact starting age and frequency (every year or every two years) can be a personal decision made with a doctor.
Cervical Cancer
Cervical cancer screening is a major public health success story. It involves two main types of tests: the Pap test, which looks for pre-cancerous cell changes on the cervix, and the HPV test, which looks for the human papillomavirus that causes most cervical cancers. Screening typically starts at age 21 and continues through age 65 for most women.
Colorectal (Colon) Cancer
Regular screening for colorectal cancer is recommended for both men and women starting at age 45. There are several different types of tests available, from at-home stool tests to visual exams like a colonoscopy. A colonoscopy is often considered the gold standard because it allows a doctor to view the entire colon and remove any pre-cancerous polyps during the procedure.
Lung Cancer
Unlike the other screenings, lung cancer screening is not recommended for the general population. Instead, it is reserved for a specific high-risk group: adults between 50 and 80 who have a significant history of smoking and either currently smoke or have quit within the past 15 years. For these individuals, a yearly low-dose CT scan is recommended to look for early signs of lung cancer.
Prostate Cancer
For men, the discussion around prostate cancer screening often involves a prostate-specific antigen (PSA) blood test. Recommendations here are less definitive, and the decision to test is usually based on a personal conversation between a man and his doctor. This discussion typically begins for men in their 50s, weighing the potential benefits of early detection against the risks of overdiagnosis and overtreatment.
Why Aren't All Cancers Screened For?
A common and very valid question is: if early detection is so important, why don't we have screening tests for every type of cancer? The answer comes down to a careful balancing act. For a screening test to be recommended for the general population, it needs to meet a high bar. The test must be able to find the cancer early, it must be accurate enough to avoid too many false positives, and most importantly, finding the cancer early must lead to better health outcomes and save lives.
Unfortunately, for many types of cancer, we don't yet have a test that meets all of these criteria. Some cancers are too rare to make population-wide screening practical, while for others, the available tests aren't sensitive or specific enough. In some cases, even when we can find a cancer early, treating it doesn't actually change a person's long-term survival. This is why the list of routinely recommended screenings is relatively short, it’s limited to the cancers where we have strong evidence that the benefits of screening clearly outweigh the harms.
The Role of Expert Guidelines
The responsibility for weighing this evidence falls to independent expert panels. In the United States, the most influential is the U.S. Preventive Services Task Force (USPSTF). This group of volunteer medical experts systematically reviews all the available data on a preventive service and issues evidence-based recommendations. Their guidelines are what most doctors use to inform their screening advice. These guidelines are incredibly valuable for public health, but they are designed for the "average" person. They represent a starting point, not the final word on an individual’s personalized health strategy.
What is the Galleri® Cancer Screening Test?
The Galleri® multi-cancer early detection test from GRAIL represents a fundamentally different approach to cancer screening.
Instead of looking at one organ at a time, the test analyzes fragments of cell-free DNA that tumors shed into the bloodstream. These fragments carry distinct epigenetic patterns - specifically DNA methylation signals -that differ between healthy and cancer cells.
If a cancer signal is detected, the test can also predict where in the body the cancer is most likely coming from.
Unlike single biomarkers or organ-specific tests, methylation patterns are:
- Present across many cancer types
- Detectable at early stages
- Highly specific to cancer biology
Rather than screening one cancer at a time, the test can screen for a signal associated with 50+ cancer types, including many with no routine screening today, such as pancreatic, ovarian, liver, and certain blood cancers.
How Galleri Complements Standard Screenings
Think of the Galleri test as a wide-angle lens for your health, designed to work alongside the close-up shots provided by standard screenings. Established tests like mammograms, Pap tests, and colonoscopies are incredibly effective and remain the gold standard for detecting specific cancers. The goal of any screening is to find cancer earlywhen treatment is most effective, and these routine checks are a critical part of that process. They can even identify pre-cancerous changes, allowing for intervention before cancer ever develops.
The Galleri test doesn’t replace these essential screenings. Instead, it fills in the significant gaps by searching for signals associated with more than 50 types of cancer, many of which have no recommended screening test today. It’s a blood test that provides a broader survey of your body’s health, acting as a powerful complement to your existing routine. The official recommendation is to use this test in addition to, not as a substitute for, the single-cancer screenings your doctor advises based on your age, gender, and risk factors.
Important Details: Test Frequency and Cost
The Galleri test is designed to be taken once a year, fitting seamlessly into an annual health review. This cadence allows you to build a consistent, year-over-year picture of your health, which aligns perfectly with a proactive approach to longevity. At Axo Longevity, we believe in the power of regular, in-depth analysis, using advanced diagnostics to track your body’s systems over time. Integrating an annual multi-cancer screening provides another layer of valuable data for your long-term health strategy.
Currently, the Galleri test is not typically covered by insurance, so it is an out-of-pocket investment in your health. More importantly, the results require professional interpretation. This isn't a standalone diagnostic; it's a screening tool that informs the next steps in your care. That’s why it’s essential to work with a healthcare provider to develop a personalized screening plan. At Axo, we help our members understand what these results mean within the full context of their health and create an actionable plan based on a complete biomarker analysis.
Your Next Step in Proactive Health
Cancer survivors often speak about “luck”: I’m so lucky I caught it early, I’m lucky they found it, I’m one of the lucky ones.
But with a disease this prevalent, outcomes shouldn’t be so heavily influenced by chance and timing.
We can’t control everything about cancer. But we can improve how we look for it. We can strengthen our screening strategies so they’re designed to surface signals earlier, rather than waiting for symptoms to demand action. And we can expand what we screen for.
Nearly 70% of cancer-related deaths are caused by cancers with no recommended screening .4 For many of these cancers, there's no standard age to begin testing, no annual reminder, no established protocol. That reality reflects the limits of the technology that was available, and a reactive system built around those constraints.
But those constraints are changing.
Advances in blood-based multi-cancer early detection now allow us to look more broadly across cancer types.Tests like Galleri surface information earlier, mitigate surprise, and provide more options and time for decisions.
That’s why we offer Galleri: to expand access to advanced testing you wouldn't typically get in standard care, and give you more control in your health.
Important Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined, by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high- complexity testing. The Galleri test is intended for clinical purposes.
Integrating Advanced Diagnostics into a Longevity Plan
A true longevity plan is more than just optimizing your daily habits. It’s about creating a strategic defense against future health risks, with advanced diagnostics as a core component. When you can identify potential issues like cancer before they spread, you have more treatment options and survival rates can be significantly higher. Integrating a test like Galleri shifts your approach from reactive to proactive, giving you a more complete picture of your health. It’s about using cutting-edge science to find information that standard check-ups might miss, especially for the many cancers that lack routine screening protocols.
This doesn't mean you should skip your regular screenings. Instead, advanced tests complement them by providing a wider, more detailed view. At Axo Longevity, we see this as a key piece of your personal health framework. We integrate insights from tests like Galleri with a deep analysis of over 100 other biomarkers covering your metabolic, hormonal, and cardiovascular health. This comprehensive approach allows us to build a truly personalized plan that addresses your unique risks and goals. By combining multi-cancer screening with our in-depth biomarker tracking, you get a clear, actionable strategy for managing your long-term well-being. You can learn more about what we test to see how these pieces fit together.
Frequently Asked Questions
Why do I need a multi-cancer test if I already get regular screenings? Think of your standard screenings, like mammograms or colonoscopies, as specialists. They are incredibly good at looking for one or two specific types of cancer and remain the most effective tools for that job. A multi-cancer test like Galleri acts more like a general survey, searching for signals from dozens of other cancers that we don't have routine screening for. It's designed to cover the gaps left by traditional methods, giving you a much broader view of your health.
Does the Galleri test replace my standard cancer screenings? No, absolutely not. The Galleri test is meant to be used in addition to your regular screenings, not as a substitute for them. You should continue with all the standard tests recommended by your doctor, such as mammograms, Pap tests, and colonoscopies. These screenings are proven to save lives and can sometimes find pre-cancerous changes, which is something the Galleri test isn't designed to do.
Who should consider taking the Galleri test? The test is officially recommended for adults who have a higher risk for cancer, like those age 50 and older. However, it's also a valuable tool for anyone who wants to be more proactive about their long-term health. If you're looking for a more comprehensive picture than what a standard physical can provide, and you want to screen for cancers that aren't typically looked for, this test can be an important part of your personal health strategy.
What happens if my test result comes back with a "Cancer Signal Detected"? A "Cancer Signal Detected" result is not a diagnosis. It's an indicator that you and your doctor need to investigate further. The test also provides a prediction of where in the body the signal might be coming from, which helps guide the next steps. This usually involves targeted imaging or other diagnostic procedures to determine if cancer is actually present. The goal of the test is to provide information that helps you and your doctor make more informed decisions.
Why isn't this test covered by insurance or part of a standard check-up? Because this type of multi-cancer screening technology is still quite new, it hasn't been widely adopted into the standard guidelines that insurance companies and public health systems follow. It often takes many years for new tests to become a routine part of care. For now, it's available as an out-of-pocket option for individuals who want to incorporate more advanced diagnostics into their personal health plan.
Key Takeaways
- Rethink your reliance on standard screening alone: Essential tests like mammograms and colonoscopies are a great start, but they only look for a few specific cancers, leaving significant gaps in a truly proactive health strategy.
- Expand your screening with a multi-cancer test: New blood tests can detect signals for over 50 types of cancer, many of which have no other screening method available. This complements your routine checks by providing a much broader view of your health.
- Build a comprehensive health picture: A multi-cancer test is one powerful tool in a larger longevity plan. Combining its insights with regular biomarker tracking and standard screenings gives you the data needed to create a truly personalized strategy for your long-term health.
